Advanced

Disease modification in OA — will we ever get there?

Lohmander, L. Stefan LU and Roos, Ewa M. LU (2019) In Nature Reviews Rheumatology
Abstract

No drugs are currently approved that change the natural course of osteoarthritis (OA) and translate to long-term, clinically relevant benefits. Two-stage clinical trial designs for OA have now received FDA approval, but remaining challenges lie in defining suitable study populations, surrogate outcomes and pivotal long-term, clinically relevant trial endpoints.

Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Nature Reviews Rheumatology
publisher
Nature Publishing Group
external identifiers
  • pmid:30733580
  • scopus:85061242517
ISSN
1759-4790
DOI
10.1038/s41584-019-0174-1
language
English
LU publication?
yes
id
62ac21d7-beb8-43c0-a5be-bffd91c0ac69
date added to LUP
2019-02-20 09:32:04
date last changed
2019-12-03 02:02:13
@misc{62ac21d7-beb8-43c0-a5be-bffd91c0ac69,
  abstract     = {<p>No drugs are currently approved that change the natural course of osteoarthritis (OA) and translate to long-term, clinically relevant benefits. Two-stage clinical trial designs for OA have now received FDA approval, but remaining challenges lie in defining suitable study populations, surrogate outcomes and pivotal long-term, clinically relevant trial endpoints.</p>},
  author       = {Lohmander, L. Stefan and Roos, Ewa M.},
  issn         = {1759-4790},
  language     = {eng},
  month        = {02},
  publisher    = {Nature Publishing Group},
  series       = {Nature Reviews Rheumatology},
  title        = {Disease modification in OA — will we ever get there?},
  url          = {http://dx.doi.org/10.1038/s41584-019-0174-1},
  doi          = {10.1038/s41584-019-0174-1},
  year         = {2019},
}